Arbutus Biopharma Corporation Q3 FY2023 earnings call

• Pipeline optimization: Discontinued coronavirus research and oral RNA destabilizer, focusing on imdusiran and AB-101.
• Workforce reduction: 24% reduction in workforce, maintaining discovery research in HBV.
• Imdusiran updates: Phase 2a clinical trial with Barinthus Bio-therapeutics, presenting data at AASLD on combination with VTP-300; potential addition of low dose PD-1 inhibitor nivolumab.
• AB-101 updates: Phase 1a/1b trial, single ascending dose in healthy subjects, data expected in first half 2024.
• Bill Collier's retirement: To end of year, Mike McElhaugh to succeed as interim CEO effective January 1st.

No detailed financial breakdown by product segments provided. Focus is on pipeline and clinical programs with imdusiran and AB-101 as key assets.

• Cash runway extended to fund operations into first quarter 2026.
• Expect data readouts for imdusiran and AB-101 in 2024, including Phase 2a data from imdusiran trial and initial data from AB-101's single ascending dose in healthy subjects.

• Forward-looking statements subject to risks detailed in SEC filings.
• Pipeline execution risks, including clinical trial recruitment challenges and potential delays in data readouts.

Q: Congrats to Bill on retirement and Mike on promotion. Questions on AB-101 results, preclinical studies, seroconversion, hepatitis delta.

A: Karen Sims discussed AB-101 Phase 1a study structure, data disclosure timeline; Michael Sofia talked about preclinical studies for AB-101 and hepatitis delta considerations.

Q: Questions about GSK deal, LNP litigation.

A: Michael Sofia commented on GSK deal as positive for hepatitis B field, no new news on LNP litigation.

Q: Questions about nivolumab trial timeline, AB-101 enrollment.

A: Bill Collier and Karen Sims discussed nivolumab trial timeframe and AB-101 enrollment details.

Q: Questions about nivolumab trial timeframe, AB-101 enrollment and combination with imdusiran.

A: Bill Collier and Karen Sims provided insights on nivolumab trial timeline and AB-101 enrollment, noting combination with imdusiran is a future aim.